

## Ninety Nine Restaurant & Pub receives Jimmy Fund's highest honor



Last summer, the Boston Red Sox presented the Ninety Nine Restaurant & Pub with the 2016 Boston Red Sox Jimmy Fund Award, the Jimmy Fund's highest honor, in recognition of its longstanding commitment to Dana-Farber's lifesaving mission.

The Ninety Nine has been a champion of Dana-Farber since 2006, when Team Lanzoni was created in memory of friend and colleague Dave Lanzoni, after he passed away from cancer. Each year, the team participates in the Falmouth Road Race, Pan-Mass Challenge, and other activities, and the restaurant has raised more than \$1.2 million through in-store promotions since 2011. In total, the Ninety Nine has raised more than \$3.2 million for Dana-Farber and the Jimmy Fund.

Above (from left), Red Sox Chairman Tom Werner, Red Sox President Sam Kennedy, Jimmy Fund Co-Captain Brock Holt, and Chairman of the Jimmy Fund Larry Lucchino present the award to Ninety Nine President Charlie Noyes and Regional Vice President Jim Kiley.

## The Lustgarten Foundation propels new pancreatic cancer treatment approaches



### The Lustgarten Foundation

recognizes that improved therapeutic strategies are needed for patients with pancreatic cancer, which is often diagnosed at an advanced stage. Toward this goal, The Lustgarten Foundation awarded Brian Wolpin, MD, MPH, co-director of Dana-Farber's Pancreas and Biliary Tumor Center, a \$379,407 grant to support his innovative work, which aims to better predict patient response to various therapies, ensuring that patients rapidly receive the most effective care.

"This generous support from The Lustgarten Foundation has enabled me to assemble a team of experts in pancreatic cancer biology and genomics to evaluate current

treatments and new approaches for patients with advanced disease," said Wolpin. "We are uncovering biomarkers to pinpoint tumor types that are most likely to respond to promising therapies, including a synthetic form of vitamin D."

In preclinical studies, vitamin D drugs have been shown to block cells that prevent cancer-fighting immune cells and chemotherapy drugs from reaching the tumor. Wolpin's work is elucidating the best candidates for this treatment.

"The Lustgarten Foundation is committed to supporting work that will reveal new strategies for the prevention, diagnosis, and treatment of pancreatic cancer, one of the most challenging-to-treat forms of cancer," said Kerri Kaplan, president and chief executive officer of The Lustgarten Foundation. "We are proud to partner with Dana-Farber to advance research that steers us ever closer to our shared goal of helping more patients with this devastating disease." ■

## Cancer Research Institute funds research on combination immunotherapies for melanoma



**CANCER RESEARCH INSTITUTE**

The Leader in Immunotherapy

The Cancer Research Institute (CRI) has awarded a \$175,000 CRI Irvington Postdoctoral Fellowship to Adam Cartwright, PhD, to develop combination immunotherapies to treat melanoma.

Using research models of melanoma, Cartwright will identify a comprehensive list of targets that can be treated with a combination of immunotherapy agents. He aims to increase the scope and efficacy

of combination immunotherapy treatments, as current regimens are successful for only a relatively small percentage of patients.

"The Cancer Research Institute understands that the keys to unlocking the immune system's full power to combat cancer lie in basic discoveries in immunology and tumor immunology, discoveries that young scientists like Dr. Cartwright make or contribute to when carrying out their postdoctoral fellowships," said Jill O'Donnell-Tormey, PhD, CEO and director of scientific affairs, Cancer Research Institute.

The Cancer Research Institute Irvington Postdoctoral Fellowship Program provides funding for young scientists to ensure that they receive

the critical financial support required to pursue their work. CRI supports research to develop immunological methods for treating, controlling, and preventing cancer.

"Funding from the CRI Irvington Postdoctoral Fellowship not only ensures that our work can continue to develop novel treatments for cancer, but more importantly, the recognition from such a prestigious foundation provides even further inspiration to discover new therapies," said Cartwright, a postdoctoral fellow in the laboratory of Kai Wucherpfennig, MD, PhD, chair of Cancer Immunology and Virology at Dana-Farber. ■

